Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CompassHER2 RD
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- NCT04457596 ↗
- Active, not recruiting
- Alliance for Clinical Trials in Oncology
- Standard
We haven't built an HCP commentary report on CompassHER2 RD (trastuzumab emtansine and tucatinib in Anatomic Stage II Breast Cancer AJCC v8) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CompassHER2 RD so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 6 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma; Anatomic Stage I Breast Cancer AJCC v8
- Interventions
- Trastuzumab Emtansine; Placebo Administration; Tucatinib; Questionnaire Administration; Quality-of-Life Assessment
- Arms
- Arm I (trastuzumab emtansine, placebo) · Active comparator
- Arm II (trastuzumab emtansine, tucatinib) · Experimental
- Enrollment
- 1,056
- Primary outcomes
- Modified invasive disease-free survival (iDFS)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI), Seagen Inc.
- Start
- Mar 2, 2021
- Primary completion
- Jan 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04457596 · updated Jun 15, 2026
Publications
linked from the registry- Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093. PubMed 40073831
- O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. PubMed 34636255